| Identification | Back Directory | [Name]
3-Pyridinecarbonitrile, 6-[(2R)-4-[7-chloro-4-(phenylmethyl)-1-phthalazinyl]-2-methyl-1-piperazinyl]- | [CAS]
1538574-95-6 | [Synonyms]
3-Pyridinecarbonitrile, 6-[(2R)-4-[7-chloro-4-(phenylmethyl)-1-phthalazinyl]-2-methyl-1-piperazinyl]- | [Molecular Formula]
C26H23ClN6 | [MOL File]
1538574-95-6.mol | [Molecular Weight]
454.95 |
| Hazard Information | Back Directory | [Description]
S1PL-IN-31 is an inhibitor of the sphingosine-1-phosphate (S1P)-catabolizing enzyme S1P Lyase (S1PL) and an antagonist of the 7-transmembrane helical protein Smoothened. | [Uses]
S1PL-IN-31 (compound ) is an oral active sphingosine-1-phosphate (S1P) lyase inhibitor with the IC50 of 210 nM. S1PL-IN-31 is Smoothened receptor antagonist with the IC50 of 440 nM. S1PL-IN-31 can be used for study of experimental autoimmune encephalomyelitis[1][2]. | [References]
[1] Weiler S, et al. Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J Med Chem. 2014;57(12):5074-5084. DOI:10.1021/jm500338n
[2] Harris CM, et al. Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats. J Pharmacol Exp Ther. 2016;359(1):151-158. DOI:10.1124/jpet.116.235002 |
|
|